# Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children

> **NCT07137884** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 150 (estimated)

## Conditions studied

- Rhabdomyosarcoma Recurrent
- Maintenance Treatment

## Interventions

- **DRUG:** Anlotinib+Cyclophosphamide+Vinorelbine
- **DRUG:** Cyclophosphamide+Vinorelbine

## Key facts

- **NCT ID:** NCT07137884
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-10-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07137884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07137884, "Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07137884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*